Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir

Although entecavir has been shown to have good efficacy and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a favorable response remain unknown.

[1]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[2]  M. Mendizabal,et al.  Effectiveness of entecavir in chronic hepatitis B NUC‐naive patients in routine clinical practice , 2011, International journal of clinical practice.

[3]  M. Buti,et al.  Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response , 2011, Hepatology.

[4]  M. Yuen,et al.  Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety , 2011, The American Journal of Gastroenterology.

[5]  P. Hu,et al.  Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis , 2011, Virology Journal.

[6]  Y. Liaw.  Impact of hepatitis B therapy on the long‐term outcome of liver disease , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[7]  K. Tanikawa,et al.  Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. , 2010, Journal of hepatology.

[8]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[9]  Stefan Zeuzem,et al.  Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. , 2009, Journal of hepatology.

[10]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[11]  M. Yuen,et al.  Chronic hepatitis B--new goals, new treatment. , 2008, The New England journal of medicine.

[12]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[13]  Y. Liaw,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2007, The New England journal of medicine.

[14]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[15]  A. MarioCalvo,et al.  Tratamiento de infección por virus de hepatitis B con entecavir A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Chang T, Gish R G, de Man R, Gadano A. N Engl J Med 2006; Vol 354: 1001-10 , 2006 .

[16]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[17]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[18]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[19]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[20]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[21]  Ding‐Shinn Chen,et al.  From hepatitis to hepatoma: lessons from type B viral hepatitis. , 1993, Science.

[22]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[23]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[24]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[25]  G. Liss,et al.  Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B , 2008 .

[26]  J. Stockman,et al.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .

[27]  J. Stockman,et al.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[28]  D. Snydman.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .